drugset / Trial / NCT01981681
A Phase 1 Study To Evaluate Tolerability, Safety, And Pharmacokinetics Of Topical PF-06263276 In Healthy Subjects
RandomizedParallel-groupTriple-blindBasic science
Summary
PF-06263276 is a first in class inhibitor of the Janus kinase (JAK) enzymes 1, 2, 3 and tyrosine kinase 2 (TYK2) that is being developed for the treatment of chronic plaque psoriasis. The goal of the study is to assess the safety, local tolerability, and pharmacokinetics in healthy subjects.
Timeline
- Start
- 2013-11
- Primary completion
- 2014-06
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF06263276 | Small molecule | 1.14 mg | Topical |
| Subject | PF06263276 | Small molecule | 2 % | Topical |
| Subject | PF06263276 | Small molecule | 2.28 mg | Topical |
| Subject | PF06263276 | Small molecule | 4 % | Topical |
| Subject | PF06263276 | Small molecule | 11.4 mg | Topical |
| Subject | PF06263276 | Small molecule | 22.8 mg | Topical |
Indications
No indication recorded.